SCHEMBL23784372

SCHEMBL23784372

COc1cc2c(cc1OCCCN1CCCC1)[nH]c1ccnc(OC3CCNC3)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EHMT2 Q96KQ7 16/20 0.48
▸ EHMT1 Q9H9B1 9/20 0.48
▸ NSD2 O96028 1/20 0.46
▸ SPIN1 Q9Y657 1/20 0.45
▸ DNMT1 P26358 4/20 0.44
▸ TLR9 Q9NR96 1/20 0.42
▸ TLR7 Q9NYK1 1/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ GAK O14976 1/20 0.42
▸ EPHB6 O15197 1/20 0.42
▸ RIPK2 O43353 1/20 0.42
▸ ERN1 O75460 1/20 0.42
▸ STK10 O94804 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ CHEK2 O96017 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ EGFR P00533 1/20 0.42
▸ ERBB2 P04626 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ FYN P06241 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL20581322 0.93 EHMT2 (0.45) EHMT2EHMT1NSD2SPIN1DNMT1
SCHEMBL20580549 0.88 EHMT2 (0.49) EHMT2EHMT1SPIN1DNMT1
SCHEMBL20581827 0.87 EHMT2 (0.48) EHMT2EHMT1SPIN1DNMT1PLK4
SCHEMBL23784392 0.86 EHMT2 (0.48) EHMT2EHMT1NSD2DNMT1
SCHEMBL30448630 0.86 EHMT2 (0.48) EHMT2EHMT1NSD2DNMT1
SCHEMBL23784361 0.86 EHMT2 (0.57) EHMT2EHMT1SPIN1TLR9TLR7
SCHEMBL20581132 0.86 EHMT2 (0.47) EHMT2EHMT1NSD2DNMT1TLR9
Hydrochloric Acid SCHEMBL20581014 0.86 EHMT2 (0.56) EHMT2EHMT1SPIN1TLR9TLR7
SCHEMBL23784401 0.83 EHMT2 (0.53) EHMT2EHMT1SPIN1PLK4GAK
SCHEMBL20581091 0.83 EHMT2 (0.53) EHMT2EHMT1SPIN1DNMT1TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634962-B1 AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-05-24 — — EP disclosed
US-20210371417-A1 AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2021-12-02 — — US disclosed
US-11111243-B2 Azaindole compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-09-07 — — US disclosed
CN-110997671-A Azaindole compounds as histone methyltransferase inhibitors 全球血液疗法股份有限公司 2020-04-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11111243-B2 Azaindole compounds as histone methyltransferase inhibitors EHMT2, EHMT1, EZH2 EHMT2 1/4885EHMT1 2/4885NSD2 96/4885
US-20210371417-A1 AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT2, EHMT1, EZH2 EHMT2 1/4885EHMT1 2/4885NSD2 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback